The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / The Many Facets of JIA: Insights from Bench to Bedside for the Clinical Care of Patients with JIA

The Many Facets of JIA: Insights from Bench to Bedside for the Clinical Care of Patients with JIA

July 18, 2021 • By Jason Liebowitz, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

PRSYM—During the virtual 2021 Pediatric Rheumatology Symposium (PRSYM), a respected trio of speakers discussed three important topics in the management of juvenile idiopathic arthritis (JIA): spondyloarthropathy, temporomandibular joint (TMJ) involvement and imaging.

You Might Also Like
  • Treatment Factors to Consider in Patients with JIA
  • Pediatric to Adult Care Transition Challenging for Patients with JIA
  • Achieving Excellence in Pediatric Rheumatology Clinical Care
Explore This Issue
August 2021
Also By This Author
  • Lessons from Master Clinicians: An Interview with Dr. Michael Weisman

Spondyloarthropathy

Leading off the session, Pamela Weiss, MD, MSCE, associate professor of pediatrics and epidemiology at the University of Pennsylvania, Philadelphia, and attending and clinical research director at the Children’s Hospital of Philadelphia, spoke about what’s new with regard to spondyloarthropathy in patients with JIA. Her talk was organized around the pathogenesis of disease, imaging of axial disease and management.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Establishing the role HLA-B27 plays in the pathogenesis of spondyloarthritis (SpA) remains challenging. HLA-B27 appears to be implicated in aberrant bone formation and Th17 T cell formation, explaining several aspects of axial and peripheral spondyloarthritis. Additionally, the intracellular effects of misfolded HLA-B27 may be involved in increased osteoblast mineralization and bone formation. Finally, reduced clonal expansion and increased T cell receptor diversity have been seen in ankylosing spondylitis, and HLA-B27 may be connected to the presentation of arthritogenic peptides.1

With regard to enthesitis, although rheumatoid arthritis (RA) targets the synovium, the spondyloarthropathies target the skeletal anchorage points for tendons, ligaments and joint capsules—also known as entheses. Systemic overexpression of interleukin (IL) 23 appears to differentiate the immunobiology of SpA from that of RA. Although the blockade of the IL-23 pathway has shown great clinical success in treating enthesitis of the peripheral skeleton, IL-23 inhibition has been less effective in the mainly spinal polyenthesitis of ankylosing spondylitis.2

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Weiss noted that it remains to be seen if IL-23 inhibition in early juvenile SpA, which is predominantly a peripheral enthesitis, will be successful.

Imaging: Dr. Weiss presented data from a study she led examining the diagnostic utility of pelvic radiographs compared with magnetic resonance imaging (MRI) of the sacroiliac joints in pediatric patients with suspected sacroiliitis. In this retrospective, cross-sectional study, radiographs and MRIs performed within six months of each other in children with suspected or confirmed SpA were independently scored by five raters. The study found misclassification for both negative and positive radiographs was high across raters. These findings imply that pelvic radiographs likely have limited utility in screening for sacroiliitis in children, especially when compared with MRI, which had superior inter-rater reliability.3

With respect to management, Dr. Weiss stated that emerging therapies, including inhibitors of IL-17A, of the heterodimer IL-17A/F, and of the Janus kinase-signaling transducer and activator of transcription (JAK/STAT) pathway, show promise in providing effective treatments for adults and children with SpA. Treatments targeting IL-17A and IL-23 may be promising for recalcitrant peripheral enthesitis.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions, Meeting Reports Tagged With: imaging, patient care, Pediatric, Pediatric Rheumatology, Pediatric Rheumatology Symposium, PRSYM, spondyloarthropathy, temporomandibular joint (TMJ)Issue: August 2021

You Might Also Like:
  • Treatment Factors to Consider in Patients with JIA
  • Pediatric to Adult Care Transition Challenging for Patients with JIA
  • Achieving Excellence in Pediatric Rheumatology Clinical Care
  • Manifestations of JIA: JIA-Associated Uveitis, sJIA & Lung Involvement in sJIA

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)